Roger Waltzman Net Worth

Roger Waltzman biography

Dr. Roger Waltzman M.D. serves as Chief Medical Officer of the Company. From April 2017 to January 2019, Dr. Waltzman was the Chief Medical Officer of Rgenix, Inc. where he supervised the development of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b clinical trials. From April 2016 to April 2017, Dr. Waltzman was the Chief Medical Officer and Chief Scientific Officer of Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. where he led scientific aspects of development and commercialization of Mytesi® (crofelemer) for patients with HIV and diarrhea, as well as development programs in chemotherapy-induced diarrhea and various indications for companion and production animals. Dr. Waltzman was also a director of Jaguar Health, Inc. from April 2016 to April 2017. From January 2007 to April 2016, Dr. Waltzman held various positions at Novartis Pharmaceuticals Corporation, including as Executive Director and Full Development Head of Malaria Drug Development from 2013 to 2016, where he played a leading role in the development of highly successful Novartis branded oncology drugs, Glivec® (imatinib) and Jakafi® (ruxolitinib). Prior to joining the pharmaceutical industry, Dr. Waltzman held assistant professorships in medical oncology and palliative care at Saint Vincent’s Hospital and Mount Sinai School of Medicine in New York. At Saint Vincent’s Hospital, he was responsible for overseeing oncology care for patients with breast, gastrointestinal, gynecologic, thoracic, and AIDS-related malignancies. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Waltzman earned an M.B.A. at Columbia Business School where he graduated valedictorian, an M.D. from Brown University School of Medicine and a B.A. from Brown University.

What is the salary of Roger Waltzman?

As the Chief Medical Officer of Molecular Templates Inc, the total compensation of Roger Waltzman at Molecular Templates Inc is $1,316,420. There are 1 executives at Molecular Templates Inc getting paid more, with Eric Poma having the highest compensation of $1,733,740.

How old is Roger Waltzman?

Roger Waltzman is 52, he's been the Chief Medical Officer of Molecular Templates Inc since 2019. There are 7 older and 12 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.

What's Roger Waltzman's mailing address?

Roger's mailing address filed with the SEC is C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD., SUITE 100, AUSTIN, TX, 78729.

Insiders trading at Molecular Templates Inc

Over the last 7 years, insiders at Molecular Templates Inc have traded over $22,993,582 worth of Molecular Templates Inc stock and bought 14,744,530 units worth $82,519,716 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., David Hirsch, and Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of $532,718. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth $587,500.

What does Molecular Templates Inc do?

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.

Molecular Templates Inc executives and stock owners

Molecular Templates Inc executives and other stock owners filed with the SEC include:

• Eric Poma,
  Chief Executive Officer, Chief Scientific Officer, Director
• Roger Waltzman,
  Chief Medical Officer
• Jason Kim,
  President, Chief Operating Officer
• Adam Cutler,
  Chief Financial Officer, Treasurer, Secretary
• Dr. Eric E. Poma,
  CEO, Chief Scientific Officer & Director
• Dr. Roger J. Waltzman M.B.A., M.D.,
  Chief Medical Officer
• Jason S Kim,
  Pres & COO
• Dr. Roger J. Waltzman,
  Chief Medical Officer
• Corazon Sanders,
  Independent Director
• Harold Selick,
  Chairman of the Board
• Kevin Lalande,
  Independent Director
• David Hirsch,
  Independent Director
• David Hoffmann,
  Independent Director
• Scott Morenstein,
  Independent Director
• Jonathan Lanfear,
  Independent Director
• Michael Dowd,
  Sr. VP of Project & Alliance Management
• Megan C. Filoon,
  Gen. Counsel & Sec.
• Dr. Nenad Sarapa M.D., M.S.,
  Sr. VP of Clinical Devel.
• Dr. Jen-Sing Liu Ph.D.,
  Exec. VP of Manufacturing
• Dr. Erin Willert Ph.D.,
  Exec. VP of R&D
• Dr. Jack Higgins Ph.D.,
  Exec. VP of Operations & Head of Manufacturing
• Kurt Elster,
  Exec. VP of Corp. Devel.
• Sean McLennan,
  Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer
• Associates, L.L.C.Morenstei...,
  
• Target N Vbb Biotech Ag Bio...,
  
• Dave Hoffmann,
  Director
• Capital Partners Iii, Llc L...,
  
• Scott Dcdk Associates, L.L....,
  
• Management Services, Llc Cu...,
  
• Sean Mc Lennan,
  See remarks
• Management Services, Llc Cu...,
  
• Gabriela Gruia,
  Director
• Maurizio Voi,
  Chief Medical Officer